01What is botulinum toxin — the molecule, the brands, the FDA history
Botulinum toxin is a neuromodulator — a purified protein that temporarily blocks the chemical signal from nerves to muscles. When injected into a target muscle (frown lines, crow's feet, masseter for jawline-slimming), the muscle relaxes for 3–4 months.
The wrinkles caused by repeated muscle contraction smooth out; the jawline slims as the masseter atrophies. The molecule itself fully clears the body within 6 months.
Type A is the cosmetic-medical variant — there are 7 botulinum toxin types in nature, but only Type A is approved for aesthetic use. All FDA-approved botulinum toxin products use the same Type A molecule: onabotulinumtoxinA (Allergan Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), prabotulinumtoxinA (Jeuveau).
Korean alternatives Hutox (clostridium botulinum toxin Type A) and Neuronox (clostridium botulinum toxin Type A from Medytox) use the same molecule with KFDA approval but different manufacturing chain.
What's NOT the same across brands: the accessory complex proteins that surround the toxin molecule in each product. Allergan Botox: large complex protein envelope.
Dysport: smaller complex protein. Xeomin: NO complex protein (pure 150 kDa toxin).
These complex proteins affect onset speed, diffusion pattern in tissue, and — critically — the body's immune response over years of repeat treatment. Same molecule, different presentation.
FDA approval history: Allergan Botox (1989 ophthalmic, 2002 cosmetic). Dysport (2009 cosmetic, 1991 EU).
Xeomin (2010 cosmetic, 2005 EU). Jeuveau (2019 cosmetic).
Korean alternatives (Hutox, Neuronox) hold KFDA + Thai FDA approval but NOT US FDA. We carry all five at Waleerat because patient profiles differ.
02The 5 brands — what makes each behave differently
Allergan Botox (onabotulinumtoxinA). The original — FDA-approved 1989.
Largest published safety dataset in aesthetic medicine, 30+ years of clinical evidence. Complex protein envelope is the largest among Type A products — this produces predictable diffusion patterns and the longest available safety track record.
Most physicians worldwide trained on Allergan. Premium tier (฿8,000 / area at Waleerat).
Best for patients who prioritise the longest available clinical track record.
Dysport (abobotulinumtoxinA). Smaller complex protein envelope than Allergan — produces SLIGHTLY wider diffusion pattern per unit.
Onset is faster: 2–4 days vs 3–7 for Allergan. Dose conversion is roughly 2.5:1 Dysport units : Allergan units — NOT a 1:1 swap.
The faster onset profile makes Dysport preferred for patients on time-sensitive timelines (wedding, photoshoot, business launch). Premium tier (฿6,000 / area).
Xeomin (incobotulinumtoxinA). The 'naked' toxin — purified to remove the complex protein envelope entirely.
Pure 150 kDa toxin without accessory proteins. Clinical implication: immune system has nothing extra to recognise and antibody-attack, so long-term resistance risk is significantly lower.
For first-time patients the practical difference is small; for 5+ year repeat users it's material. Mid tier (฿5,000 / area).
Best for patients planning long-term repeat treatment.
Hutox (Korean Type A). Manufactured by Huons (South Korea), KFDA + Thai FDA approved.
Same Type A molecule as the Big-3 above, but shorter clinical history (KFDA 2013, Thai FDA 2018). Value tier (฿3,000 / area).
Best for patients on budget who want a regulator-approved botulinum toxin but don't need the longest clinical track record.
Neuronox (Korean Type A). Manufactured by Medytox, the older of the two major Korean Type A products. KFDA + Thai FDA approved. Similar profile to Hutox. Value tier (฿3,000–฿4,000 / area).
03Decision tree — match the brand to the patient profile
Profile A — first-time botulinum patient, NOT planning long-term repeat use. Recommendation: Allergan or Dysport.
The decision between them is timeline-driven: pick Dysport if you have an event in 1–2 weeks (faster onset matters); pick Allergan if you have 2+ weeks before the event (the longer-evidence safety profile matters more than onset speed at that timeline).
Profile B — repeat botulinum user (3+ years of treatment, every 3–4 months). Recommendation: Xeomin.
The pure-toxin formulation reduces immune-resistance risk that compounds over years of repeat exposure. Even though the per-treatment difference vs Allergan is small, over a 5–10 year repeat schedule the cumulative risk profile favors Xeomin materially.
Profile C — value-tier patient on budget, first-time or occasional use. Recommendation: Hutox or Neuronox.
Same Type A molecule with KFDA + Thai FDA approval. The shorter clinical history is acceptable for first-time or occasional users; the budget tier (฿3,000–฿4,000 per area) makes botulinum accessible without compromising regulator-approved safety.
Profile D — large treatment zone (jawline-slimming masseter, forehead-broad, body) where uniform diffusion matters. Recommendation: Dysport.
The slightly wider diffusion pattern per unit is well-matched to larger zones where uniform spread is desirable. For point-precision work (lip-flip, crow's-feet outer edge) the smaller diffusion of Xeomin is preferable instead.
When to NOT pick botulinum toxin at all: pregnancy / breastfeeding (no safety data); neuromuscular disease (Myasthenia gravis, Lambert-Eaton syndrome); active infection at injection site; allergy to any component (rare); aminoglycoside antibiotic use within 2 weeks (potentiates effect). These are standard exclusions; the consultation confirms candidacy.
045-row comparison table — what we show at every consult
Active molecule: All five = Botulinum Toxin Type A. Same neuromuscular mechanism, same target (acetylcholine release from motor neuron).
Complex protein envelope: Allergan = large. Dysport = smaller. Xeomin = none (pure 150 kDa). Hutox = present. Neuronox = present.
Onset: Allergan 3–7 days. Dysport 2–4 days (fastest). Xeomin 3–5 days. Hutox 4–7 days. Neuronox 4–7 days. Peak effect = 14 days across all five.
Duration: All five = 3–4 months average. Range 2–5 months depending on individual metabolism, dose, and treatment zone (larger muscles like masseter hold longer).
Bangkok 2026 price (Waleerat): Allergan ฿8,000 / area. Dysport ฿6,000 / area. Xeomin ฿5,000 / area. Hutox / Neuronox ฿3,000–฿4,000 / area.
Regulatory: Allergan, Dysport, Xeomin — FDA + Thai FDA + KFDA + EU CE Mark. Hutox, Neuronox — KFDA + Thai FDA (NOT US FDA). All five pass Thai FDA — choice is clinical and budget, not safety.
05Brand choice by facial zone — where each formulation outperforms
Frown lines (glabella) + forehead horizontal lines: any of the five works well. The zone is well-vascularised, the target muscles are large enough to tolerate small variation in diffusion.
We default to Allergan or Dysport for premium patients, Xeomin for repeat users, Hutox/Neuronox for budget.
Crow's feet (lateral periorbital): point precision matters because diffusion into adjacent muscles (zygomaticus, levator labii) causes droopy smile. Xeomin's pure formulation has tighter diffusion control.
Allergan also works well. Avoid wider-diffusion Dysport for this zone unless administered by an experienced injector who can compensate.
Jawline slimming (masseter): large muscle, uniform diffusion is GOOD here. Dysport's slightly wider diffusion pattern is well-matched.
Dose required is high (20–30 units per side for Allergan, 50–75 units per side for Dysport). We typically use Dysport or Allergan for first-time masseter; Hutox for maintenance.
Lip flip + perioral fine lines: highest precision zone — small muscles, lip motion critical, low tolerance for diffusion error. Xeomin OR Allergan only.
Dysport's wider diffusion can cause asymmetric lip movement; Korean brands' shorter clinical history is not preferred for this delicate zone.
Sleepy-eye (medial brow): muscle is small and adjacent to the levator palpebrae — diffusion error causes upper-lid ptosis (the brow droops). Xeomin or Allergan ONLY, by experienced injector.
We don't run Hutox or Dysport for sleepy-eye at Waleerat regardless of patient budget.
Trapezius + neck lines: large body muscles, Dysport's wider diffusion is well-matched. High dose required (100–150 units per side Dysport for trapezius). See /services/botox-trapezius for the dedicated protocol.
06Why immune resistance matters — the long-term consideration most clinics don't discuss
Over years of repeat botulinum treatment, the immune system can develop neutralising antibodies that reduce the toxin's effectiveness. The antibodies target the complex protein envelope (NOT the toxin itself) — which is why Xeomin's pure-toxin formulation has lower long-term resistance risk than Allergan or Dysport.
Practical impact: a patient who starts botulinum at age 30 and treats every 4 months will receive ~90 treatments by age 60. At that volume of exposure, complex-protein antibody formation becomes clinically meaningful — the patient's botulinum 'stops working' (reduced duration, weaker effect, requiring higher doses to achieve the same result).
Xeomin is the only Type A botulinum without complex protein — it presents only the 150 kDa toxin core that the immune system has trouble building antibodies against (the core is too similar to the body's natural neurotransmitter machinery to be flagged as foreign). For patients planning 20+ years of repeat treatment, this is a material consideration.
When we recommend Xeomin specifically: patients in their 30s starting long-term treatment, patients who've used Allergan/Dysport for 5+ years and noticed reduced duration, patients with documented allergy/sensitivity to other botulinum products. For occasional or first-time use, the practical difference vs Allergan is small enough that brand choice can be driven by other factors (onset speed, budget, physician familiarity).
هل أنت مستعد للتحدث مع طبيبنا؟
أرسل صورة أو صف مشكلتك على LINE — سنقترح خطة علاجية ونطاقًا سعريًا قبل زيارتك.